Background: Prasugrel is a novel third-generation thienopyridine P2Y12 receptor antagonist with more rapid, potent, and consistent platelet inhibition than clopidogrel. [23] Aim: Compare the ...

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...

Elinogrel (PRT060128 or PRT128) (Figure 3) is a direct-acting, reversible P2Y 12 antagonist (Figure 5) that can be administered both intravenously and orally. This unique dual formulation provides ...

Switzerland-based Idorsia has been developing P2Y12 inhibitor selatogrel to improve ... The dual endothelin receptor antagonist, also known as aprocitentan, has been available since October ...